e-learning
resources
Paris 2018
Tuesday, 18.09.2018
Biomarkers of COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The impact of high eosinophil count on hospitalizations in COPD patients
B. Arpinar Yigitbas (Istanbul, Turkey), E. Niksarlioglu (Istanbul, Turkey), E. Yazar (Istanbul, Turkey), L. Kilic (Istanbul, Turkey), C. Satici (Istanbul, Turkey), S. Ozden (Istanbul, Turkey)
Source:
International Congress 2018 – Biomarkers of COPD
Session:
Biomarkers of COPD
Session type:
Thematic Poster
Number:
4068
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Arpinar Yigitbas (Istanbul, Turkey), E. Niksarlioglu (Istanbul, Turkey), E. Yazar (Istanbul, Turkey), L. Kilic (Istanbul, Turkey), C. Satici (Istanbul, Turkey), S. Ozden (Istanbul, Turkey). The impact of high eosinophil count on hospitalizations in COPD patients. 4068
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Association between blood eosinophil count and risk of exacerbations in patients with COPD
Source: International Congress 2017 – Biomarker-based asthma control
Year: 2017
Blood eosinophil count and exacerbation risk in patients with COPD
Source: Eur Respir J, 50 (1) 1700761; 10.1183/13993003.00761-2017
Year: 2017
Blood eosinophil count and risk of pneumonia hospitalisations in individuals with COPD
Source: Eur Respir J, 51 (5) 1800120; 10.1183/13993003.00120-2018
Year: 2018
Association between blood eosinophil counts and risk of rehospitalization in patients with asthma
Source: International Congress 2017 – Monitoring novel biomarkers in asthma
Year: 2017
Blood eosinophil (EOS) count, exacerbation rate and response to roflumilast in patients with severe COPD
Source: International Congress 2017 – What is new in COPD management and prognosis: findings from large studies?
Year: 2017
Correlations between exacerbation rate and blood eosinophil levels in COPD patients
Source: International Congress 2017 – Infection and exacerbation science
Year: 2017
Effect of COPD exacerbations on early lung function decline under maintenance therapy: blood eosinophil count asbiomarker
Source: International Congress 2019 – Eosinophils and FeNO in airway diseases
Year: 2019
Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute exacerbation of COPD.
Source: International Congress 2017 – Highlights on clinical problems in COPD
Year: 2017
The rate of re-exacerbation in patients hospitalized with eosinophil and non-eosinophilic COPD relapses
Source: Virtual Congress 2020 – Phenotypes of obstructive diseases
Year: 2020
Blood eosinophil count predicts treatment failure and hospital readmission for COPD
Source: ERJ Open Res, 6 (4) 00188-2020; 10.1183/23120541.00188-2020
Year: 2020
Eosinophil counts as a predictor of future COPD exacerbations in the DYNAGITO trial
Source: International Congress 2019 – Eosinophils and FeNO in airway diseases
Year: 2019
Mepolizumab in patients =3 exacerbations and eosinophil count =300 cells/µL
Source: International Congress 2017 – Asthma management
Year: 2017
Relationship of blood eosinophil count to exacerbations in COPD
Source: International Congress 2016 – Airway response to infection
Year: 2016
The impact of eosinophil levels on current prescribing in COPD
Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils
Year: 2020
Elevated blood eosinophils on admission for a severe exacerbation of COPD is not a predictor for survival
Source: International Congress 2017 – COPD: from screening to risk factors of lung cancer
Year: 2017
Definition of COPD phenotype depending on eosinophil count
Source: Virtual Congress 2020 – News on clinical evaluation of bronchiectasis, cough and inflammatory disease
Year: 2020
Accuracy of blood eosinophil count in predicting sputum eosinophils in children with problematic severe asthma (PSA)
Source: Virtual Congress 2020 – Novel mechanisms and management of paediatric asthma
Year: 2020
The blood eosinophil count as a biomarker in COPD
Source: International Congress 2015 – Individualised risk reduction strategies for patients with COPD
Year: 2015
Does the infection influence on induced sputum cell count at smokers and nonsmokers with COPD exacerbation?
Source: Annual Congress 2009 - Exacerbations of COPD and bronchiectasis: aetiology and treatment
Year: 2009
Variability in eosinophil levels at start of severe exacerbations of COPD
Source: Virtual Congress 2020 – Diagnosis and management of COPD
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept